UCB SA Revenue

UCB SA had revenue of 2.79B EUR in the half year ending June 30, 2024, a decrease of -2.24%. This brings the company's revenue in the last twelve months to 5.45B, up 3.32% year-over-year. In the year 2023, UCB SA had annual revenue of 5.18B, down -4.87%.

Revenue (ttm)

5.45B

Revenue Growth

+3.32%

P/S Ratio

5.92

Revenue / Employee

606.00K

Employees

9,083

Market Cap

32.23B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	5.18B	-265.00M	-4.87%
Dec 31, 2022	5.45B	-330.00M	-5.71%
Dec 31, 2021	5.78B	430.00M	8.04%
Dec 31, 2020	5.35B	434.00M	8.83%
Dec 31, 2019	4.91B	281.00M	6.07%
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro
Dec 31, 2014	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

UCB SA News

22 hours ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
22 hours ago - FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease - Benzinga
1 day ago - UCB gets FDA approval for Bimzelx for hidradenitis suppurativa - Seeking Alpha
1 day ago - Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - Seeking Alpha
9 days ago - United Community Banks: Too Rich For My Blood - Seeking Alpha
5 weeks ago - Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy - Seeking Alpha
7 weeks ago - UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024 - Benzinga
2 months ago - UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024 - Benzinga

More News